A 4-year cohort study of the effects of PNPLA3 rs738409 genotypes on liver fat and fibrosis and gut microbiota in a non-fatty liver population.

Satoshi SATO; Chikara IINO; Takafumi SASADA; Keisuke FURUSAWA; Kenta YOSHIDA; Kaori SAWADA; Tatsuya MIKAMI; Shinsaku FUKUDA; Shigeyuki NAKAJI; Hirotake SAKURABA

Return

A 4-year cohort study of the effects of PNPLA3 rs738409 genotypes on liver fat and fibrosis and gut microbiota in a non-fatty liver population.

Author: Satoshi SATO ¹ ; Chikara IINO ¹ ; Takafumi SASADA ¹ ; Keisuke FURUSAWA ¹ ; Kenta YOSHIDA ¹ ; Kaori SAWADA ² ; Tatsuya MIKAMI ² ; Shinsaku FUKUDA ² ; Shigeyuki NAKAJI ² ; Hirotake SAKURABA ¹
Author Information

1. Department of Gastroenterology, Hematology and Clinical Immunology, Hirosaki University Graduate School of Medicine.
2. Department of Preemptive Medicine, Hirosaki University Graduate School of Medicine.
Publication Type:Journal Article
Keywords: Cohort study; Gut microbiota; Liver fat; Liver fibrosis; Patatin-like phospholipase domain-containing 3 (PNPLA3)
MeSH: Humans; Gastrointestinal Microbiome; Male; Female; Membrane Proteins/metabolism*; Lipase/genetics*; Middle Aged; Liver Cirrhosis/epidemiology*; Cohort Studies; Genotype; Adult; Non-alcoholic Fatty Liver Disease/microbiology*; Polymorphism, Single Nucleotide; Acyltransferases; Phospholipases A2, Calcium-Independent
From:Environmental Health and Preventive Medicine 2025;30():17-17
CountryJapan
Language:English
Abstract: BACKGROUND:Many factors are associated with the development and progression of liver fat and fibrosis; however, genetics and the gut microbiota are representative factors. Moreover, recent studies have indicated a link between host genes and the gut microbiota. This study investigated the effect of patatin-like phospholipase domain-containing 3 (PNPLA3) rs738409 (C > G), which has been reported to be most involved in the onset and progression of fatty liver, on liver fat and fibrosis in a cohort study related to gut microbiota in a non-fatty liver population.
METHODS:This cohort study included 214 participants from the health check-up project in 2018 and 2022 who had non-fatty liver with controlled attenuation parameter (CAP) values <248 dB/m by FibroScan and were non-drinkers. Changes in CAP values and liver stiffness measurement (LSM), liver-related items, and gut microbiota from 2018 to 2022 were investigated separately for PNPLA3 rs738409 CC, CG, and GG genotypes.
RESULTS:Baseline values showed no difference among the PNPLA3 rs738409 genotypes for any of the measurement items. From 2018 to 2022, the PNPLA3 rs738409 CG and GG genotype groups showed a significant increase in CAP and body mass index; no significant change was observed in the CC genotype group. LSM increased in all genotypes, but the rate of increase was highest in the GG genotype, followed by the CG and CC genotypes. Fasting blood glucose levels increased in all genotypes; however, HOMA-IR (Homeostasis Model Assessment of Insulin Resistance) increased significantly only in the GG genotype. HDL (high-density lipoprotein) and LDL (low-density lipoprotein) cholesterol levels significantly increased in all genotypes, whereas triglycerides did not show any significant changes in any genotype. As for the gut microbiota, the relative abundance of Feacalibacterium in the PNPLA3 rs738409 GG genotype decreased by 2% over 4 years, more than 2-fold compared to CC and GG genotypes. Blautia increased significantly in the CC group.
CONCLUSION:The results suggest that PNPLA3 G-allele carriers of non-fatty liver develop liver fat and fibrosis due to not only obesity and insulin resistance but also the deterioration of gut microbiota, which may require a relatively long course of time, even years.